Radiotherapy is one of the most common countermeasures for treating a wide range of
tumors. However, the radioresistance of cancer cells is still a major limitation for …

A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …

DNA damage response (DDR) pathway prevents high level endogenous and environmental
DNA damage being replicated and passed on to the next generation of cells via an …

Alterations in DNA damage response (DDR) pathways are hallmarks of cancer. Incorrect
repair of DNA lesions often leads to genomic instability. Ataxia telangiectasia mutated …

Over the last decades, the growing understanding on DNA damage response (DDR)
pathways has broadened the therapeutic landscape in oncology. It is becoming increasingly …

Glioma is one of the most common and lethal brain tumors. Surgical resection followed by
radiotherapy plus chemotherapy is the current standard of care for patients with glioma. The …

ATM is a key mediator of radiation response, and pharmacological inhibition of ATM is a
rational strategy to radiosensitize tumors. AZD1390 is a brain-penetrant ATM inhibitor and a …

Glioblastoma multiforme (GBM) is a severe brain tumor whose ability to mutate and adapt to
therapies is at the base for the extremely poor survival rate of patients. Despite multiple …

Human checkpoint kinase ataxia telangiectasia-mutated (ATM) plays a key role in initiation
of the DNA damage response following DNA double-strand breaks. ATM inhibition is a …